Lazcluze 80mg film-coated tablets

Lazcluze in combination with amivantamab is indicated for the first‑line treatment of adult patients with advanced non‑small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.

Treatment with Lazcluze should be initiated by a physician experienced in the use of anticancer medicinal products.

Before initiation of Lazcluze, EGFR mutation-positive status in tumour tissue or plasma specimens must be established using a validated test method. If no mutation is detected in a plasma specimen, tumour tissue should be tested if available in sufficient amount and quality due to the potential for false negative results using a plasma test.

Posology

The recommended dose of Lazcluze is 240 mg once daily in combination with amivantamab.

It is recommended to administer Lazcluze any time prior to amivantamab when given on the same day. Refer to section 4.2 of the amivantamab Summary of Product Characteristics for recommended amivantamab dosing information.

Venous thromboembolic (VTE) events with concomitant use with amivantamab

At the initiation of treatment, prophylactic anticoagulants are recommended to be used for the first four months of treatment. Consistent with clinical guidelines, patients should receive prophylactic dosing of appropriate anticoagulants, e.g. low‑molecular weight heparin (LMWH). Use of Vitamin K antagonists is not recommended.

Skin and nail reactions

Prophylactic therapy with oral and topical antibiotics is recommended to reduce the risk and severity of skin and nail reactions in patients receiving Lazcluze in combination with amivantamab. Non-comedogenic skin moisturiser (ceramide-based or other formulations that provide long-lasting skin hydration and exclude drying agents are preferred) on the face and whole body (except scalp) and chlorhexidine solution to wash hands and feet is also recommended. Patients should be instructed to limit sun exposure during and for 2 months after Lazcluze combination therapy. For further information about prophylaxis for VTE and skin and nail reactions, see section 4.4.

Duration of treatment

Treatment should continue until disease progression or unacceptable toxicity.

Missed dose

If a planned dose of Lazcluze is missed, it can be administered within 12 hours. If more than 12 hours have passed since the dose was to be given, the missed dose should not be administered and the next dose should be administered per the usual dosing schedule.

Dose modifications

The recommended dose reductions for adverse reactions are presented in Table 1.

Dose modifications for specific adverse reactions are presented in Table 2.

Refer to section 4.2 of the amivantamab Summary of Product Characteristics for information about dose modifications for amivantamab.

Special populations

Elderly

No dose adjustment is required (see sections 4.8, 5.1 and 5.2).

Renal impairment

Based on population pharmacokinetics (PK) analysis, no dose adjustment is required for patients with mild, moderate or severe renal impairment. Data in patients with severe renal impairment are limited. The PK of lazertinib in patients with end stage renal disease is unknown. Caution is required in patients with end‑stage renal disease (see section 5.2).

Hepatic impairment

No dose adjustment is required for patients with mild or moderate hepatic impairment. The PK of lazertinib in patients with severe hepatic impairment is unknown. Caution is required in patients with severe hepatic impairment (see section 5.2).

Paediatric population

There is no relevant use of lazertinib in the paediatric population for the treatment of non‑small cell lung cancer.

Method of administration

Lazcluze is for oral use. The tablets should be swallowed whole with or without food. Tablets should not be crushed, split, or chewed.

If vomiting occurs any time after taking Lazcluze, the next dose should be taken the next day.

Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.

Interstitial lung disease/pneumonitis

Interstitial lung disease (ILD) or ILD‑like adverse reactions (e.g., pneumonitis), including fatal events, have been reported in patients treated with lazertinib and amivantamab (see section 4.8). Patients with a medical history of ILD, drug‑induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD were excluded from the pivotal clinical study. Patients should be monitored for symptoms indicative of ILD/pneumonitis (e.g., dyspnoea, cough, fever). If symptoms develop, treatment with Lazcluze should be interrupted pending investigation of these symptoms. Suspected ILD or ILD-like adverse reactions should be evaluated and appropriate treatment should be initiated as necessary. Lazcluze should be permanently discontinued in patients with confirmed ILD or ILD‑like adverse reactions (see section 4.2).

Venous thromboembolic (VTE) events

In patients receiving Lazcluze in combination with amivantamab, venous thromboembolic (VTE) events, including deep venous thrombosis (DVT) and pulmonary embolism (PE), including fatal events were reported (see section 4.8). VTE events occured predominantly in the first four months of therapy. Prophylactic anticoagulants are recommended to be used for the first four months of treatment (see section 4.2 and 4.8). Consistent with clinical guidelines, patients should receive prophylactic dosing of appropriate anticoagulants, e.g. LMWH. Use of Vitamin K antagonists is not recommended.

Signs and symptoms of VTE events should be monitored. Patients with VTE events should be treated with anticoagulation as clinically indicated. For VTE events associated with clinical instability, treatment should be withheld until the patient is clinically stable. Thereafter, both medicinal products can be resumed at the same dose, at the discretion of the treating physician.

In the event of recurrence despite appropriate anticoagulation, discontinue Lazcluze or amivantamab. Treatment can continue with either Lazcluze or amivantamab, but not both, at discretion of the treating physician (see section 4.2).

Skin and nail reactions

Rash (including dermatitis acneiform), pruritus and dry skin occurred in patients treated with lazertinib in combination with amivantamab (see section 4.8). Patients should be instructed to limit sun exposure during and for 2 months after Lazcluze combination therapy. Protective clothing and use of broad‑spectrum UVA/UVB sunscreen are advisable. A prophylactic approach to rash prevention is recommended. This includes prophylactic therapy, at treatment initiation, with an oral antibiotic starting on Day 1 for the first 12 weeks of treatment and after completion of oral antibiotic therapy, topical antibiotic lotion to the scalp for the next 9 months of treatment. Non‑comedogenic skin moisturiser (ceramide-based or other formulations that provide long-lasting skin hydration and exclude drying agents are preferred) on the face and whole body (except scalp) and chlorhexidine solution to wash hands and feet is recommended beginning on Day 1 and continued for the duration of treatment.

Prescriptions for additional topical and/or oral antibiotics and topical corticosteroids are recommended to be available at the time of initial dosing to minimise any delay in reactive management should rash develop despite prophylactic treatment.

If skin or nail reactions develop, supportive care, topical corticosteroids and topical and/or oral antibiotics should be administered. For Grade 3 or poorly‑tolerated Grade 2 events, systemic antibiotics and oral steroids should also be administered and dermatologic consultation should be considered. Lazcluze should be reduced in dose, interrupted, or permanently discontinued based on severity (see section 4.2).

Eye disorders

Eye disorders, including keratitis, occurred in patients treated with lazertinib in combination with amivantamab (see section 4.8). Patients presenting with worsening eye symptoms should promptly be referred to an ophthalmologist and should discontinue use of contact lenses until symptoms are evaluated.

Excipients

This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially “sodium‑free”.

Strong CYP3A4 inducers can decrease lazertinib plasma concentrations. Lazertinib may increase the plasma concentrations of CYP3A4 and BCRP substrates.

Agents that may alter lazertinib plasma concentrations

CYP3A4 inducers

The co‑administration of multiple doses of rifampicin (strong CYP3A4 inducer) decreased lazertinib C_max by 72% and AUC by 83% in healthy subjects. The co‑administration of Lazcluze with strong CYP3A4 inducers (e.g. carbamazepine, phenytoin, rifampicin, St. John's wort) should be avoided. The co‑administration of Lazcluze with moderate CYP3A4 inducers may also decrease lazertinib plasma concentrations and hence moderate CYP3A4 inducers (e.g. bosentan, efavirenz, modafinil) should be used with caution.

CYP3A4 inhibitors

The co‑administration of multiple doses of itraconazole (strong CYP3A4 inhibitor) increased lazertinib C_max by 1.19‑fold and AUC by 1.46‑fold in healthy subjects. No initial dose adjustment is required when Lazcluze is co‑administered with CYP3A4 inhibitors.

Gastric acid reducing agents

No clinically relevant differences in lazertinib pharmacokinetics were observed when co‑administered with gastric acid reducing agents (proton pump inhibitors and H2‑receptor antagonists). No dose adjustments are required when Lazcluze is used with gastric acid reducing agents.

Agents that may have their plasma concentrations altered by Lazcluze

CYP3A4 substrates

The co‑administration of multiple doses of 160 mg Lazcluze once daily increased midazolam (CYP3A4 substrate) C_max by 1.39‑fold and AUC by 1.47‑fold. Narrow therapeutic index medicinal products that are CYP3A4 substrates (e.g., cyclosporine, everolimus, pimozide, quinidine, sirolimus, tacrolimus) should be used with caution, as lazertinib may increase the plasma concentrations of these medicinal products.

BCRP substrates

The co‑administration of multiple doses of 160 mg Lazcluze once daily increased rosuvastatin (BCRP substrate) C_max by 2.24‑fold and AUC by 2.02‑fold. Narrow therapeutic index medicinal products that are BCRP substrates (e.g., sunitinib) should be used with caution, as lazertinib may increase the plasma concentrations of these medicinal products.

CYP1A2 substrates

Induction of CYP1A2 cannot be excluded. Therefore, caution is advised when co-administering with substrates of CYP1A2 (e.g., tizanidine).

Women of childbearing potential/Contraception in males and females

Women of childbearing potential should be advised to use effective contraception during treatment and up to 3 weeks after treatment.

Male patients with female partners of reproductive potential should be advised to use effective contraception (e.g., condom) and not donate or store semen during treatment and for 3 weeks after the last dose of lazertinib.

Pregnancy

There are no data from the use of lazertinib in pregnant women. Studies in animals have shown reproductive toxicity (reduced embryo‑foetal survival and foetal body weight) (see section 5.3). Based on its mechanism of action and animal data, lazertinib may cause foetal harm when administered to a pregnant woman. Lazertinib should not be used during pregnancy unless the benefit of treatment of the woman is considered to outweigh potential risks to the foetus. If the patient becomes pregnant while taking this medicinal product the patient should be informed of the potential risk to the foetus.

Breast‑feeding

It is unknown whether lazertinib or its metabolites are excreted in human milk or affects milk production. Because the risk to the breast‑feeding child cannot be excluded, female patients should be advised not to breastfeed during treatment and for 3 weeks after the last dose of lazertinib.

Fertility

There are no data on the effect of Lazcluze on human fertility. Studies in animals have shown that lazertinib has effects on reproductive organs in females (decreased numbers of oestrus cycles and corpora lutea) and males (degenerative changes in the testis) and may impair female and male fertility (see section 5.3).

Lazcluze has minor influence on the ability to drive and use machines. If patients experience treatment related symptoms (such as fatigue) affecting their ability to concentrate and react, it is recommended that they do not drive or use machines until the effect subsides.

Summary of the safety profile

The most frequent adverse reactions in all grades were rash (89%), nail toxicity (71%), infusion‑related reaction (amivantamab only) (63%), hypoalbuminaemia (amivantamab only) (48%), hepatotoxicity (47%), oedema (amivantamab only) (47%), stomatitis (43%), venous thromboembolism (37%), paraesthesia (34%), fatigue (32%), constipation (29%), diarrhoea (29%), dry skin (26%), decreased appetite (24%), pruritus (24%), hypocalcaemia (21%), other eye disorders (21%) and nausea (21%).

The most frequent serious adverse reactions included venous thromboembolism (11%), pneumonia (4.0%), rash (3.1%), interstitial lung disease/pneumonitis (2.9%) , COVID‑19 (2.4%), hepatotoxicity (2.4%), pleural effusion (2.1%), infusion‑related reaction (amivantamab only) (2.1%), respiratory failure (1.4%), fatigue (1.2%), oedema (amivantamab only) (1.2%), hypoalbuminaemia (amivantamab only) (1.2%), and hyponatraemia (1.2%).

The most frequent adverse reactions leading to any treatment discontinuation in patients receiving Lazcluze in combination with amivantamab were rash (6%), infusion‑related reaction (amivantamab only) (4.5%), nail toxicity (3.6%), interstitial lung disease/pneumonitis (2.9%), venous thromboembolism (2.9%), pneumonia (1.9%) and oedema (amivantamab only) (1.7%).

Tabulated list of adverse reactions

Table 3 summarises the adverse reactions that occurred in patients receiving lazertinib in combination with amivantamab.

The data reflects exposure to lazertinib in 421 patients who received lazertinib in combination with amivantamab in MARIPOSA. The median exposure to lazertinib was 18.5 months (range: 0.2 to 31.4 months).

Adverse reactions observed during clinical studies are listed below by frequency category. Frequency categories are defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000); very rare (< 1/10 000); and not known (frequency cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.

Description of selected adverse reactions

Venous thromboembolic (VTE)

Venous thromboembolic (VTE) events, including deep vein thrombosis (14.5%) and pulmonary embolism (PE) (17.3%), were reported in 37% of patients receiving lazertinib in combination with amivantamab. Most cases were Grade 1 or 2, with Grade 3‑4 events occurring in 11% and deaths occurring in 0.5% of patients receiving lazertinib in combination with amivantamab.

In patients receiving lazertinib in combination with amivantamab, the median time to first onset of a VTE event was 84 days. VTE events led to any treatment discontinuation in 2.9% of patients.

The use of prophylactic anticoagulants was evaluated in the PALOMA-3 study. PALOMA-3 is a randomised, open-label, Phase 3 study assessing subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with osimertinib and platinum-based chemotherapy. For patients treated with lazertinib in combination with IV amivantamab in PALOMA-3 that received prophylactic anticoagulation, the overall incidence of VTE events was 11%, with Grade 3 VTE events reported in 1.2% and serious VTE events reported in 1.8%.

For information on prophylactic anticoagulants and management of VTE events, see sections 4.2 and 4.4.

Interstitial lung disease (ILD)/pneumonitis

Interstitial lung disease or ILD‑like adverse reactions (e.g., pneumonitis) have been reported with the use of lazertinib in combination with amivantamab as well as with other EGFR inhibitors. ILD or pneumonitis was reported in 3.1% of patients treated with lazertinib in combination with amivantamab, including 0.2% fatal cases. Patients with a medical history of ILD, drug‑induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD were excluded from the clinical study (see section 4.4).

Skin and nail reactions

Rash (including dermatitis acneiform), pruritus and dry skin has occurred. Rash occurred in 89% of patients treated with lazertinib in combination with amivantamab. Most cases were Grade 1 or 2, with Grade 3 events occurring in 27% of patients. Rash leading to any treatment discontinuation occurred in 6% of patients. Rash usually developed within the first 4 weeks of therapy, with a median time to onset of 14 days. Nail toxicity occurred in patients treated with lazertinib in combination with amivantamab. Most events were Grade 1 or 2, with Grade 3 nail toxicity occurring in 11% of patients (see section 4.4).

A Phase 2 study in patients treated with Lazcluze in combination with amivantamab was conducted to assess the use of prophylactic therapy with an oral antibiotic, a topical antibiotic on the scalp, a moisturiser on the face and whole body (except scalp), and an antiseptic on hands and feet (see sections 4.2 and 4.4). A reduction in the incidence of ≥ Grade 2 dermatologic adverse events during the first 12 weeks of treatment was demonstrated, compared with the standard dermatologic management used in clinical practice (38.6% vs. 76.5%, p<0.0001). In addition, there was a reduction in ≥ Grade 2 adverse events involving the scalp in the first 12 weeks of treatment (8.6% vs. 29.4%) along with lower incidence of dose reductions (7.1% vs. 19.1%), interruptions (15.7% vs. 33.8%), and treatment discontinuations (1.4% vs. 4.4%) due to dermatological adverse events.

Eye disorders

Eye disorders, including keratitis (2.6%), occurred in patients treated with lazertinib in combination with amivantamab. Other reported adverse reactions included growth of eyelashes, visual impairment, and other eye disorders. Most events were Grade 1‑2 (see section 4.4).

Hepatotoxicity

Hepatotoxicity‑related reactions occurred in 47% of patients treated with lazertinib in combination with amivantamab. Most events were Grade 1‑2, with Grade 3‑4 hepatotoxicity occurring in 9% of patients. Most events were related to elevations of serum transaminases (36% alanine aminotransferase increased and 29% aspartate aminotransferase increased). Most patients with elevations of transaminases were able to continue study treatment without modification of study treatment while a small number were managed with a dose interruption or with a dose reduction. There were no cases of liver failure or fatal cases of hepatotoxicity in clinical studies with lazertinib in combination with amivantamab.

Isolated reports of alkaline phosphatase increased and prolonged elevated bilirubin have been identified with lazertinib monotherapy.

Paraesthesia

Paraesthesia occurred in 34% of patients treated with lazertinib in combination with amivantamab. Most events were Grade 1‑2, with Grade 3 paraesthesia occurring in 1.7% of patients. Most patients with paraesthesia had resolution with dose interruption or dose reduction.

Stomatitis

Stomatitis occurred in 43% of patients treated with lazertinib in combination with amivantamab. Most events were Grade 1‑2, with Grade 3 stomatitis occurring in 2.4% of patients.

Diarrhoea

Diarrhoea occurred in 29% of patients treated with lazertinib in combination with amivantamab. Most events were Grade 1‑2, with Grade 3 diarrhoea occurring in 2.1% of patients.

Special populations

Elderly

There are limited clinical data with lazertinib in patients 75 years of age or over (see section 5.1). While the rates of drug interruptions and dose reductions were similar, there was a higher incidence of Grade 3 or higher adverse events, and adverse events leading to discontinuation of treatment in patients ≥ 65 years of age treated with the combination of lazertinib with amivantamab, compared to patients <65 years of age.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

There is no known specific antidote for Lazcluze overdose. In the event of an overdose, stop Lazcluze and undertake general supportive measures. Patients should be closely monitored for signs or symptoms of adverse reactions.

Pharmacotherapeutic group: antineoplastic agents, protein kinase inhibitors, ATC code: L01EB09.

Mechanism of action

Lazertinib is an irreversible EGFR tyrosine kinase inhibitor (TKI). It selectively inhibits both primary activating EGFR mutations (exon 19 deletions and exon 21 L858R substitution mutations) and the EGFR T790M resistance mutation, while having less activity against wild‑type EGFR.

Pharmacodynamic effects

Based on the exposure‑response analyses for safety, paraesthesia and stomatitis appeared to show a trend of increasing occurrence with increase in lazertinib exposure.

Cardiac electrophysiology

The QTc interval prolongation potential of lazertinib was evaluated by exposure‑response (E‑R) analysis conducted with clinical data from 243 NSCLC patients who received 20, 40, 80, 120, 160, 240 or 320 mg lazertinib once daily in a phase 1/II study. The E‑R analysis revealed no clinically relevant relationship between lazertinib plasma concentration and change in QTc interval.

Clinical efficacy and safety

MARIPOSA is a randomised, open-label, active‑controlled, multicentre phase 3 study assessing the efficacy and safety of Lazcluze in combination with amivantamab intravenous formulation as compared to osimertinib monotherapy in the first‑line treatment of patients with EGFR‑mutated locally advanced or metastatic NSCLC not amenable to curative therapy. Patient samples were required to have one of the 6 two common EGFR mutations (exon 19 deletion or exon 21 L858R substitution mutation), as identified by local testing. Tumour tissue (94%) and/or plasma (6%) samples for all patients were tested locally to determine EGFR exon 19 deletion and/or exon 21 L858R substitution mutation status using polymerase chain reaction (PCR) in 65% and next generation sequencing (NGS) in 35% of patients.

A total of 1074 patients were randomised (2:2:1) to receive Lazcluze in combination with amivantamab, osimertinib monotherapy, or Lazcluze monotherapy until disease progression or unacceptable toxicity. Lazcluze was administered at 240 mg orally once daily. Amivantamab was administered intravenously at 1050 mg (for patients < 80 kg) or 1400 mg (for patients ≥ 80 kg) once weekly for 4 weeks, then every 2 weeks thereafter starting at week 5. Osimertinib was administered at a dose of 80 mg orally once daily. Randomisation was stratified by EGFR mutation type (exon 19 deletion or exon 21 L858R substitution mutation), race (Asian or non‑Asian), and history of brain metastasis (yes or no).

Baseline demographics and disease characteristics were balanced across the treatment arms. The median age was 63 (range: 25–88) years with 45% of patients ≥ 65 years and 11% ≥ 75 years; 62% were female; and 59% were Asian, and 38% were White. Baseline Eastern Cooperative Oncology Group (ECOG) performance status was 0 (34%) or 1 (66%); 69% never smoked; 41% had prior brain metastases; and 90% had Stage IV cancer at initial diagnosis. With regard to EGFR mutation status, 60% were exon 19 deletions and 40% were exon 21 L858R substitution mutations.

Lazcluze in combination with amivantamab demonstrated a statistically significant and clinically meaningful improvement in progression‑free survival (PFS) by BICR assessment, with a 30% reduction in the risk of progression or death compared with osimertinib (HR=0.70 [95% CI: 0.58, 0.85], p=0.0002). The corresponding median PFS was 23.72 months (95% CI: 19.12, 27.66) for the Lazcluze in combination with amivantamab arm and 16.59 months (95% CI: 14.78, 18.46) for the osimertinib arm.

The final analysis of OS demonstrated a statistically significant improvement in OS for Lazcluze in combination with amivantamab compared to osimertinib (see Table 4 and Figure 3).

With 82% of pre-specified deaths for the analysis reported, there was a favourable trend for the overall survival (OS) towards the combination of Lazcluze and amivantamab compared with osimertinib. A greater proportion of patients treated with Lazcluze in combination with amivantamab were alive at 12 months, 18 months, 24 months, 36 months and 42 months (90%, 82%,75%, 60% and 56% respectively) compared to patients treated with osimertinib (88%, 79%, 70%, 51% and 44% respectively). Lazcluze in combination with amivantamab also provided a benefit in the time to second progression or death (PFS2) (HR=0.75 [95% CI: 0.58, 0.98], p=0.0314). While the objective response rate (ORR) was comparable between the arms, the median duration of response (DOR) among confirmed responders was longer with Lazcluze in combination with amivantamab (25.76 vs 16.76 months). Lazcluze in combination with amivantamab also provided a benefit in the time to symptomatic progression (TTSP), a measure of the burden of lung cancer symptoms (HR=0.72 [95% CI: 0.57, 0.91], p=0.0049). Table 4, Figure 1 and Figure 3 summarise efficacy results for Lazcluze in combination with amivantamab.

Figure 1: Kaplan‑Meier curve of PFS in previously untreated patients with NSCLC by BICR assessment

The PFS benefit of Lazcluze in combination with amivantamab as compared to osimertinib was generally consistent across prespecified, clinically relevant subgroups, including age group, sex, race, weight, mutation type, ECOG performance status, history of smoking, and history of brain metastasis at study entry (see figure 2).

Figure 2: Forest plot of PFS in previously untreated patients with NSCLC by BICR assessment

The MARIPOSA study included protocol‑mandated brain magnetic resonance imaging (MRIs), which have historically not been used in trials evaluating EGFR‑mutated NSCLC. This may have led to earlier detection of recurrences and associated shorter median values for PFS. To account for this, a sensitivity analysis was done whereby patients with brain‑only progression as the site of first progression were censored. Extracranial PFS based on BICR assessment was consistent with the treatment benefit observed in the primary analysis. The median extracranial PFS was 27.5 months with Lazcluze in combination with amivantamab, as compared to 18.37 months with osimertinib (HR=0.68 [95% CI: 0.55, 0.83], nominal p=0.0001).

The stratified analysis of investigator‑assessed PFS shows that the improved treatment effect of the combination of Lazcluze and amivantamab relative to osimertinib was also observed when assessed by investigator. Results for the analysis of ORR based on investigator assessment for comparison of the Lazcluze in combination with amivantamab arm versus the osimertinib arm were consistent with results for ORR based on BICR assessment.

Figure 3: Kaplan‑Meier curve of OS in previously untreated patients with NSCLC

Results of pre‑specified analyses of intracranial ORR and DOR by BICR in the subset of patients with intracranial lesions at baseline for the combination of Lazcluze and amivantamab demonstrated similar intracranial ORR to the control. Per protocol, all patients in MARIPOSA had serial brain MRIs to assess intracranial response and duration. Results are summarised in Table 5.

Paediatric population

The Licensing Authority has waived the obligation to submit the results of studies with Lazcluze in all subsets of the paediatric population in non‑small cell lung cancer (see section 4.2 for information on paediatric use).

Following single and multiple once daily oral administration, lazertinib maximum plasma concentration (C_max) and area under plasma concentration time curve (AUC) increased approximately dose proportionally across 20 to 320 mg dose range.

The steady state plasma exposure was achieved by day 15 of once daily administration and approximately 2‑fold accumulation was observed at steady state with 240 mg once daily dose.

The lazertinib plasma exposure was comparable when lazertinib was administered either in combination with amivantamab or as a monotherapy.

Absorption

The median time to reach single dose and steady state C_max was comparable and ranged from 2 to 4 hours.

Following administration of 240 mg lazertinib with a high‑fat meal (800~1000 kcal, fat content approximately 50%), the C_max and AUC of lazertinib were comparable to that under fasting conditions suggesting lazertinib can be taken with or without food.

Distribution

Lazertinib was extensively distributed, with mean (CV%) apparent volume of distribution of 4264 (43.2%) L at 240 mg dose. Lazertinib mean (CV%) plasma protein binding was approximately 99.2% (0.13%) in humans. Lazertinib demonstrated covalent binding to human blood and plasma proteins after oral dosing, and during in vitro incubations.

Metabolism

Lazertinib is primarily metabolised by glutathione conjugation, either enzymatic via glutathione-S‑transferase (GST) or non‑enzymatic, as well as by CYP3A4. The most abundant metabolites are glutathione catabolites and considered clinically inactive. The plasma exposure of lazertinib was affected by GSTM1 mediated metabolism, leading to lower exposure (less than 2‑fold difference) in Non‑null GSTM1 patients. No dose adjustment is required based on GSTM1 status.

Elimination

The mean (CV%) apparent clearance and terminal half‑life of lazertinib at 240 mg dose were 44.5 (29.5%) L/h and 64.7 (32.8%) hours, respectively.

Excretion

Following a single oral dose of radiolabelled lazertinib, approximately 86% of the dose was recovered in faeces (< 5% as unchanged) and 4% in urine (< 0.5% as unchanged).

Co‑administration with OCT1 and UGT1A1 substrates

The co‑administration of multiple doses of Lazcluze did not increase metformin (OCT1 substrate) C_max and AUC. Lazcluze does not inhibit OCT1.

Based on in vitro studies, Lazcluze may inhibit UGT1A1. However, due to lack of effect on indirect bilirubin levels in clinical study, no clinically relevant interaction is expected with UGT1A1 substrates.

Special populations

Elderly

Based on population PK analysis, no clinically meaningful age‑based differences in pharmacokinetics of lazertinib were observed.

Renal impairment

Based on population PK analysis, no dose adjustment is required for patients with mild, moderate or severe renal impairment with estimated glomerular filtration rate (eGFR) of 15 to 89 mL/min. Data in patients with severe renal impairment (eGFR of 15 to 29 mL/min) are limited (n=3), but there is no evidence to suggest that dose adjustment is required in these patients. No data are available in patients with end stage renal disease (eGFR < 15 mL/min).

Hepatic impairment

Based on findings from clinical pharmacology study, moderate hepatic impairment (Child‑Pugh Class B) had no clinically meaningful effect on lazertinib single dose PK. Based on population PK analysis, no dose adjustment is required for patients with mild (total bilirubin ≤ ULN and AST > ULN or ULN < total bilirubin ≤ 1.5×ULN and any AST) or moderate (1.5×ULN < total bilirubin ≤ 3×ULN and any AST) hepatic impairment. No data are available in patients with severe hepatic impairment (total bilirubin > 3×ULN and any AST).

Paediatric population

The pharmacokinetics of lazertinib in paediatric patients have not been investigated.

Other populations

No clinically meaningful differences in lazertinib PK were observed based on sex, body weight, race, ethnicity, baseline laboratory assessments (creatinine clearance, albumin, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase), ECOG performance status, EGFR mutation type, initial diagnosis cancer stage, prior therapies, brain metastasis, and history of smoking.

The main findings observed in repeat‑dose toxicity studies with lazertinib in rats and dogs comprised mild epithelial atrophy to degenerative erosions, inflammation, and necrosis affecting the eye (corneal atrophy) skin (thin and rough hair coat, hair follicle degeneration, alopecia, ulcer), liver (increased liver enzymes, Kupffer cell hypertrophy and hepatocellular necrosis), lungs (alveolar macrophage infiltrate, lung inflammation and hyperplasia of alveolar type II cells), kidney (tubular dilatation, papillary necrosis, higher urea nitrogen, creatinine (females only), inorganic phosphorus, and potassium), GI (oesophageal epithelial atrophy, villus blunting/fusion in duodenum, and jejunum, liquid faeces), reproductive system (testis tubular degeneration, hypospermia, decreased oestrous cycles and corpora lutea, atrophy in uterus and vagina). These findings were observed in animals in exposures ranges of 0.9‑3.4x than estimated exposures of patients administered with the recommended dose (240 mg) and were fully or partially resolved during the recovery phases. The heart was considered a target organ in dog alone and occurred at exposure levels 7x to that of exposure levels expected at the human recommended dose.

Carcinogenicity and Mutagenicity

No evidence of genotoxicity for lazertinib was observed in in vitro bacterial mutagenicity, in vitro chromosomal aberration, and in vivo micronucleus tests in rats. Long‑term animal studies have not been conducted to evaluate the carcinogenic potential of lazertinib.

Reproductive Toxicology

Based on studies in animals, male and female fertility may be impaired by treatment with lazertinib. Degenerative changes were present in the testes of rats and dogs resulting in reduced luminal sperm in dogs following exposure to lazertinib for 1 month at clinically relevant exposure levels. Decreased numbers of corpora lutea were noted in the ovaries of rats exposed to lazertinib for ≥ 1 month at clinically relevant exposure levels. In a fertility and early embryonic development study in male and female rats, lazertinib induced a decrease in the number of oestrus cycles, an increase in post‑implantation loss and decreased live litter size at or below the dose level that approximated the human clinical exposure at the recommended dose of 240 mg.

Developmental toxicity was observed in embryo‑foetal development studies in rats and rabbits. In rats, decreases in foetal body weights in association with maternal toxicity were observed at a maternal exposure approximately 4 times higher than the human clinical exposure at 240 mg. In rabbits, an increased incidence of a foetal skull bone fusion (zygomatic arch fused to the maxillary process) was observed at maternal exposures well below the human clinical exposure at 240 mg.

Tablet Core

silica, hydrophobic colloidal

croscarmellose sodium (E 468)

cellulose, microcrystalline (E 460 (i))

mannitol (E 421)

magnesium stearate (E 572)

Film Coating

macrogol poly(vinyl alcohol) grafted copolymer (E 1209)

polyvinyl alcohol (E 1203)

glycerol monocaprylocaprate type I (E 471)

titanium dioxide (E 171)

talc (E 553b)

yellow iron oxide (E 172)

Not applicable

2 years

This medicinal product does not require any special storage conditions.

Blister pack

Polyvinyl chloride – polychlorotrifluoroethylene (PVC‑PCTFE) film and aluminium push‑through foil.

  • One carton contains 56 film-coated tablets (2 wallet packs containing 28 tablets each).

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.